Upstream Interventions for Managing Obesity in Patients with Type 2 Diabetes

Upstream Interventions for Managing Obesity in Patients with Type 2 Diabetes

Upstream Interventions for Managing Obesity in Patients with Type 2 Diabetes

What’s the impact of implementing strategies for weight loss early in patients with T2D? Discover improved outcomes across the CV disease spectrum. 

Available credits: 0.25

Time to complete: 15 minutes


Valid until:

Take Post-Test

If you’ve already completed the activity.

  • Overview

    Implementing body weight reduction strategies in the treatment of patients with type 2 diabetes (T2D) has been shown to produce greater disease-modifying effects than any other glucose-lowering intervention, resulting in improved hypertension, dyslipidemia, and diabetes. By implementing an upstream intervention to weight loss, and using newer drugs (GIP agonists, GLP-1 receptor agonists, SGLT2 inhibitors), patients will experience improved effects earlier and for a longer duration.

  • Disclosure of Conflicts of Interest

    In accordance with the ACCME Standards for Integrity and Independence, Global Learning Collaborative (GLC) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any ineligible company. GLC mitigates all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational programs.

    Juan P. Frias, MD
    Medical Director and Principal Investigator
    Velocity Clinical Research
    Los Angeles, CA

    Commercial Interest Speakers Bureau: Eli Lilly, Sanofi
    Consulting Fees: 89bio, Akero, Altimmune, Axcella Health, Becton Dickinson, Boehringer Ingelheim, Carmot Therapeutics, Echosens, Eli Lilly, Gilead, Intercept, Metacrine, Merck, Novo Nordisk, Pfizer, Sanofi
    Research Support: 89bio, Akero, AstraZeneca, BMS, Boehringer Ingelheim, Eli Lilly, Intercept, IONIS, Janssen, Madrigal, Metacrine, Merck, NorthSea Therapeutics, Novartis, Novo Nordisk, Oramed, Pfizer, Poxel, Sanofi

    Donna Ryan, MD
    Professor Emerita
    Pennington Biomedical Research Center
    Baton Rouge, LA

    Commercial Interest Speakers Bureau: Novo Nordisk
    Consulting Fees: Altimmune, Amgen, Boehringer Ingelheim, Calibrate, Carmot, Epitomee, Gila Therapeutics, IFA Celtics, Lilly, Novo Nordisk, Real Appeal (UnitedHealthcare), Scientific Intake, Wondr Health, Xeno Biosciences, YSOPIA, Zealand
    Ownership Interest: Calibrate, Epitomee, Roman, Scientific Intake

    Reviewers/Content Planners/Authors:

    • Stephen Chavez has nothing to disclose.
    • Cindy Davidson has nothing to disclose.
    • Amanda Hilferty has nothing to disclose.
    • Libby Lurwick has nothing to disclose.
    • Brian P. McDonough, MD, FAAFP, has nothing to disclose.
    • Colleen Resnick has nothing to disclose.
    • Katie Sheridan, PhD, has nothing to disclose.
  • Learning Objectives

    After participating in this educational activity, participants should be better able to:

    • Identify weight loss as a primary target of treatment in people with type 2 diabetes and obesity
    • Formulate strategies to intensify individualized treatment combinations that focus on weight loss and glycemic control
  • Target Audience

    This activity is designed to meet the educational needs of endocrinologists, primary care physicians, and other professionals who manage patients who are overweight/obese with type 2 diabetes.

  • Accreditation and Credit Designation Statements

    In support of improving patient care, Global Learning Collaborative (GLC) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.



    Global Learning Collaborative (GLC) designates this enduring activity for a maximum of 0.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Global Learning Collaborative (GLC) designates this activity for 0.25 nursing contact hours. Nurses should claim only the credit commensurate with the extent of their participation in the activity.

    Global Learning Collaborative (GLC) has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 0.25 AAPA Category 1 CME credits. Approval is valid until October 20, 2023. PAs should claim only the credit commensurate with the extent of their participation in the activity. 

  • Provider(s)/Educational Partner(s)

    Prova Education designs and executes continuing education founded on evidence-based medicine, clinical need, gap analysis, learner feedback, and more. Our mission is to serve as an inventive and relevant resource for clinical content and educational interventions across a broad spectrum of specialties.
    Prova Education's methodology demonstrates a commitment to continuing medical education and the innovative assessment of its effects. Our goal is clear—to develop and deliver the very best education in the most impactful manner and to verify its results with progressive outcomes research.

  • Commercial Support

    This activity is supported by an independent educational grant from Lilly.

  • Disclaimer

    The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of GLC and Prova Education. This presentation is not intended to define an exclusive course of patient management; the participant should use his/her clinical judgment, knowledge, experience, and diagnostic skills in applying or adopting for professional use any of the information provided herein. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. Links to other sites may be provided as additional sources of information. Once you elect to link to a site outside of Prova Education you are subject to the terms and conditions of use, including copyright and licensing restriction, of that site.

    Reproduction Prohibited
    Reproduction of this material is not permitted without written permission from the copyright owner.

  • System Requirements

    Our site requires a computer, tablet, or mobile device and a connection to the Internet. For best results, a high-speed Internet connection is recommended (DSL/Cable/Fibre). We also recommend using the latest version of your favorite browser to ensure compliance with W3C standards, such as Chrome, Safari, Firefox, or Microsoft Edge.

Facebook Comments


We’re glad to see you’re enjoying Prova Education…
but how about a more personalized experience?

Register for free